Cenobamate Treatment Shows Promising 90-99% Responder Rates in seizure reduction for patients with Epilepsy

J. Serratosa et al conducted a post hoc analysis on patients who experienced a 90-99% reduction in seizures from the C017 open label extension study, suggesting that cenobamate may also provide optimal long-term outcomes for these patients – despite not being seizure free.